Company: RGBP
Filing Date: 2025-05-28
Form Type: 10-Q
Source: 0001641172-25-012619
Chunk: 17

Company: Regen BioPharma Inc
Filing Date: 2025-05-28
Form: 10-Q
Item: Part I, Item 1
Chunk 17
---
 is defined in the Agreement, in a Quarter.

Pursuant
to the Agreement, Zander will pay The Company ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market
value as monetary consideration) received by Zander from sublicensees (excluding royalties from sublicensees based on Net Sales of any
Licensed Products for which The Company receives payment pursuant to the terms and conditions of the Agreement).

Zander
is obligated pay to The Company minimum annual royalties of ten thousand US dollars ($ 10,000 10,000

The
Agreement may be terminated by The Company:

If
Zander has not sold any Licensed Product by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product
for any twelve (12) month period after Zander’s first commercial sale of a Licensed Product.

The
Agreement may be terminated by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement
a patent has not been granted by the United States patent and Trademark Office to The Company with regard to that License IP.

The
Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent
and Trademark Office to The Company with regard to that License IP is terminated.

The
Agreement may be terminated by either party in the event of a material breach by the other party.

On
December 17, 2018 Regen Biopharma, Inc.(“ Licensor”), KCL Therapeutics, Inc. (“ Assignee”) and Zander Therapeutics,
Inc. (“ Licensee”) entered into a LICENSE ASSIGNMENT AND CONSENT AGREEMENT whereby, with regards to certain intellectual property
which was assigned by Regen Biopharma, Inc.(“ Assigned Properties”) to its wholly owned subsidiary KCL Therapeutics, Inc.,
Licensor hereby transfers and assigns to Assignee all rights, duties, and obligations of Licensor under the Agreement with respect to
the Assigned Properties, and Assignee agrees to assume such duties and obligations thereunder and be bound to the terms of the Agreement
with respect thereto.

On
December 16, 2019 Zander Therapeutics, Inc. (“ Zander”), KCL Therapeutics, Inc. (“ KCL”) and Regen Biopharma, Inc.
(“ Regen”) entered into an agreement (“ Agreement”) whereby:

1)
Zander shall return for cancellation